Login| Sign Up| Help| Contact|

Patent Searching and Data


Matches 351 - 400 out of 12,397

Document Document Title
WO/2012/146774A1
The present invention concerns a compound of formula (I) the salt, solvate, enantiomer, diastereoisomer and racemic mixture thereof for treating or preventing ischemia/reperfusion injury associated disorders during surgical operations or...  
WO/2012/140596A1
The present invention provides a compound of formula I; a method for manufacturing the compounds of the invention, and its therapeutic uses. The present invention further provides a combination of pharmacologically active agents and a ph...  
WO/2012/140596A8
The present invention provides a compound of formula (I); a method for manufacturing the compounds of the invention, and its therapeutic uses. The present invention further provides a combination of pharmacologically active agents and a ...  
WO/2012/140576A1
A compound of the formula (I) wherein R1 is a group removable by hydrogenolysis,and wherein R2 is OH or R2 is -NHR3 wherein R3 is a group removable by hydrogenolysis. The compound can be made from fructose by a Heyns-rearrangement. The c...  
WO/2012/142615A3
Auranofin analogs and pharmaceutical compositions which inhibit p-STAT3 are provided together methods of synthesizing and methods of using the compounds. Also provided are methods of treating p-STAT3 diseases and disorders in a patient i...  
WO/2012/141228A1
Provided is a novel therapeutic means for Alzheimer's disease. A compound represented by general formula (I) [wherein Ar1 represents a 2-methoxy-4-(2-pyridylmethoxy)phenyl group or the like; and Ar2 represents a 1H-indole-6-yl group or t...  
WO/2012/142615A2
Auranofin analogs and pharmaceutical compositions which inhibit p-STAT3 are provided together methods of synthesizing and methods of using the compounds. Also provided are methods of treating p-STAT3 diseases and disorders in a patient i...  
WO/2012/139134A3
Described herein, at least in part, are methods of modulating oncogenic fusion proteins.  
WO/2012/132022A1
Provided is a compound represented by the formula (I): wherein R1 represents R5=N- (R5 represents a saccharide residue) or (R4 represents a mono- or polyethylene glycol residue); each of R2 and R3, whether identical or not, represents a ...  
WO/2012/129651A1
The invention provides compounds of formula (I) with substituents as specified in claim 1 for selectively inhibiting glycosidases, prodrugs of the compounds, and pharmaceuticals compositions including the compounds or prodrugs of the com...  
WO/2012/132022A9
Provided is a compound represented by the formula (I): wherein R1 represents R5=N- (R5 represents a saccharide residue) or (R4 represents a mono- or polyethylene glycol residue); each of R2 and R3, whether identical or not, represents a ...  
WO/2012/125991A3
The invention describes compositions that include a stevia sweetener and a salt of a steviol glycoside, wherein the concentration of the components provide an improved taste profile where bitterness, after taste and/or lingering of the s...  
WO/2012/119846A1
The present invention relates to synthetic lipoteicoic acid (LTA) mimeticswhich are useful as vaccine components for therapy and/or prophylaxis of bacterial infection.  
WO/2012/121394A1
The present invention provides a substituted aromatic compound represented by general formula (I) [wherein A1, A2 and A3 independently represent an aryl group substituted by a hydrophilic group].  
WO/2012/121862A2
The invention relates to valproic acid:dextran compounds and methods of using them. The invention further relates to pharmaceutical compositions and methods for treating a variety of diseases and disorders, including brain trauma, epilep...  
WO/2012/122282A1
A preparation of antibiotic hygromycin B with low cell toxicity and high purity, and methods of preparing such a preparation, are provided. More specifically, an isolated antibiotic hygromycin B with a purity of greater than 98% and impu...  
WO/2012/121862A3
The invention relates to valproic acid:dextran compounds and methods of using them. The invention further relates to pharmaceutical compositions and methods for treating a variety of diseases and disorders, including brain trauma, epilep...  
WO/2012/116447A1
A combination of a bacterial endotoxin, in particular a lipopolysaccharide, and a lipoteichoic acid for treating or preventing a metabolic disorder or bacterial infection, or for improving milk energy efficiency in a subject. The combina...  
WO/2012/113405A1
A method for the manufacture of a mixture of human milk oligosaccharides is disclosed. The method involves the catalytic hydrogenolysis of compounds of the general formula 1 and 2. The use of compounds of general formula 1 and 2 in the m...  
WO/2012/107204A1
The present invention relates to the use of the compound of formula (I) or a derivative or a stereoisomer or a salt or a hydrate thereof as a sweetness enhancer, to sweetener compositions comprising at least one sweetener and the compoun...  
WO/2012/107205A1
The present invention relates to the use of the compound of formula (I) or a derivative or a stereoisomer or a salt or a hydrate thereof as a sweetener and/or a sweetness enhancer, to sweetener compositions comprising the compound of for...  
WO/2012/104145A1
The present invention relates to an improved process for the preparation of an extract enriched in dihydrochalcones, and more specifically enriched in phlorizin, starting from a polyphenolic fraction originating from industrial apple pro...  
WO/2012/101605A1
The invention relates to the FGF receptor-activating oligosaccharides corresponding to formula (I) in which R1 represents an optionally substituted -O-alkyl group, R2 represents a hydroxyl group or an -O-alkyl group, R3, R5, R6, R7 and R...  
WO/2012/097876A1
A novel class of cell-penetrating enhancers with unusual chemical structure is herein disclosed. Said cell-penetrating enhancers are non-linear and non peptidic (guanidyl)-oligosaccharidic derivatives, which can be easily obtained accord...  
WO/2012/099477A1
The invention relates to methods of localising biofunctional moieties (F) to surfaces and synthetic constructs of the general structure F-S-S' for use in such methods. F is the biofunctional moiety, S is a spacer covalently linking F to ...  
WO/2012/097454A1
This invention relates to a compound of Formula 1A: or a pharmaceutically acceptable salt thereof: wherein R1 to R4. R7, R9 to R12 and Y are as defined herein. The invention further relates to pharmaceutical composition comprising said c...  
WO/2012/099904A1
The present invention provides novel methods for determining the presence or amount of a hydrolytic enzyme in a sample, based on novel substrates for the enzymes, and also provides compositions and methods that provide highly sensitive a...  
WO/2012/095793A3
The present invention comprises compounds of formula (I) and (II), embodying a 3-enopyranoside-2-ulose system and compound of formula (III), presenting a pyranoside α,β,γ,δ-unsaturated ester skeleton, derived from compound of formula...  
WO/2012/094752A1
A process for producing a natural sweetening enhancer composition comprising at least an Rebaudioside C (RC) extract, said process comprises the steps of preparing a saccharide mother liquor comprising an RC mass content of at least 15%;...  
WO/2012/096884A1
Provided are phenethyl isoindoline compounds, and pharmaceutically acceptable salts, solvates, or stereoisomers thereof. Methods of use and pharmaceutical compositions of these compounds are also disclosed.  
WO/2012/093091A2
The present invention relates to saccharide mimics which show a better biological activity at low concentrations as known saccharide mimics in inhibiting angiogenesis and inhibiting formation of metastasis by inhibiting adhesion and/or m...  
WO/2012/094540A2
Methods for synthesis and preparation of alpha-glycosphingolipids are provided. Methods for synthesis of α-galactosyl ceramide, and pharmaceutically active analogs and variants thereof are provided. Novel alpha-glycosphingolipids are pr...  
WO/2012/093091A3
The present invention relates to saccharide mimics which show a better biological activity at low concentrations as known saccharide mimics in inhibiting angiogenesis and inhibiting formation of metastasis by inhibiting adhesion and/or m...  
WO/2012/094540A3
Methods for synthesis and preparation of alpha-glycosphingolipids are provided. Methods for synthesis of a-galactosyl ceramides, and pharmaceutically active analogs and variants thereof are provided. Novel alpha-glycosphingolipids are pr...  
WO/2012/091570A1
A carbohydrate-containing feedstock is converted in a process, which process comprises contacting the feedstock in a first step with an alcohol in the presence of a first acid catalyst at a temperature below 100 °C to yield an intermedi...  
WO/2012/088598A1
A process for producing the natural sweetener composition which comprises at least one of steviolbioside (STB) extract, Rebaudioside B extract and Rebaudioside D extract ("collectively, the "extracts") comprises the steps of preparing a ...  
WO/2012/088612A1
A method for breeding Stevia rebaudiana with a high content of RA comprises selecting the plants in the perfect stage with a high RA content as parents and hybridizing them to produce F1 generation seeds; stabilizing the traits of the F1...  
WO/2012/088593A1
Natural steviol glycosides sweetener compositions comprise a blend of Rebaudioside C extract and at least one of Rebaudioside A extract and STV extract including methods for producing the same and uses thereof in foods, beverages, functi...  
WO/2012/085668A3
The invention provides a synthetic C. difficile PS-II cell wall saccharide. The invention also provides a process for purifying C. difficile PS-II saccharide from C. difficile bacterial cells resulting in reduced contamination. The sacch...  
WO/2012/088264A2
A cardiogenin major isomer is obtained from a methanol extract of Geum japonicum and separated from its minor isomer. The separation of the two isomers can be achieved by chiral phase chromatography, e.g., using a Chiralpak® IC™ colum...  
WO/2012/086811A1
The present invention provides a food intake suppressant and an anti-obesity agent containing the compounds represented by formula (I''). (In the formula, at least one of R11, R12, R13, R14 and R15 is a G-O- group (where G represents a s...  
WO/2012/088264A3
A cardiogenin major isomer is obtained from a methanol extract of Geum japonicum and separated from its minor isomer. The separation of the two isomers can be achieved by chiral phase chromatography, e.g., using a Chiralpak® IC™ colum...  
WO/2012/086812A1
The present invention provides the compounds represented by formula (I''), a method for producing the compounds, and GLP-1 secretagogues etc. containing the compounds. (In the formula, at least one of R11, R12, R13, R14 and R15 is a G-O-...  
WO/2012/082677A1
Sweetener compositions comprising particular glycoside blends are described in this paper. The glycioside blends comprise rebaudioside A, rebaudioside B, and/or rebaudioside D in various proportions. The sweetener composition can also in...  
WO/2012/082587A3
The invention relates to a process for producing highly soluble compositions containing purified steviol glycosides from Stevia rebaudiana Bertoni plant extract, more particularly Rebaudioside D. Obtained highly soluble compositions are ...  
WO/2012/082493A1
A process for production of crystalline rebaudioside B from rebaudioside A is described. Additionally, four distinct crystal polymorphic forms of rebaudioside B are described, as well as methods for converting from one crystal polymorphi...  
WO/2012/082650A3
The present invention relates to novel aminoglycoside analogs having certain substituents at the 6 position of ring III which exhibit improved antifungal activity but possess minimal antibacterial properties. The compounds of the present...  
WO/2012/082650A2
The present invention relates to novel aminoglycoside analogs having certain substituents at the 6 position of ring III which exhibit improved antifungal activity but possess minimal antibacterial properties. The compounds of the present...  
WO/2012/079039A1
A preparation of antibiotic G418 with low cell toxicity and high purity, and methods of preparing such a preparation, are provided. More specifically, an isolated antibiotic G418 with a purity of greater than 95% and no individual group ...  
WO/2012/073214A3
Compounds having the general formula (I) pharmaceutical compositions containing them for use in inhibiting bacterial heptose biosynthesis and thereby lowering or suppressing bacterial virulence.  

Matches 351 - 400 out of 12,397